Antithymocyte globulin, horse ATG (Atgam)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Contains antibodies against T-cell markers including CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD44, CD45, Beta-2 microglobulin, HLA Class I heavy chains, and HLA-DR. Exact mechanism not understood, but may involve removing T-cells from circulation and modifying T-cell activation, migration, proliferation, and cytotoxic effects.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in EMA indication

  • 1981-11-17: EURD

Also known as

Note: different brands of horse ATG are likely to be from different host animals and will thus have different constituents; they should not be considered necessarily interchangeable.

  • Brand names: Atgam, Lymphoglobuline, Thymogam